Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Sojo now focuses on the development of business-to-business propositions and is adopting an in-house operations model.

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...